Jul 25 2024
Healthcare
Recent Research
hVIVO, H1 trading statement
Jul 17 2024
hVIVO, Influenza field study contract
Jul 2 2024
CVS Group, Non-core disposals
May 21 2024
hVIVO, FY2023 results
Apr 9 2024
Uniphar, Focus on the target
Apr 3 2024
Meet your Healthcare Research team
CVS Group
Full year 2024 trading update
CVS Group’s expected FY24 adjusted EBITDA of c.£127m is moderately below our current forecasts (Davy: c.£131m), with the transitory effect of the previously announced cyber incident...
hVIVO
H1 trading statement
hVIVO has issued a trading statement for H1 2024 ahead of its Capital Markets Day later today. Revenue guidance for 2024 is unchanged and is H1 weighted. EBITDA margins are stronger...
hVIVO
Influenza field study contract
Following on from the milestone Omicron contract win announced last month, hVIVO has announced its largest ever field study contract to test an influenza drug candidate, which will...
hVIVO
Omicron contract win provides significant opportunity
hVIVO has signed an important new contract to initiate an Omicron characterisation study. Omicron is a variant of COVID-19. The study will utilise its new quarantine facilities in Canary...
CVS Group
Non-core disposals
CVS has announced the disposal of its non-core and loss-making operations in The Netherlands and Ireland for a nominal sum. This enables the company to focus on its key UK market and...
hVIVO
FY2023 results
hVIVO made significant progress in 2023 with multiple challenge contracts signed and a record number of volunteers inoculated. Top-line growth of 16% drove margin expansion and led to...
Uniphar
Focus on the target
We believe that the headwinds that held back Uniphar’s stock in 2022-2023 are now in the past. The outlook is far more positive. We estimate that achieving its medium-term EBITDA...
CVS Group
CMA provisionally launching a formal market investigation
The Competition and Markets Authority (CMA) announced yesterday (March 12th) that its initial review into the vets market has identified multiple concerns. It has provisionally launched...
CVS Group
H1 2024 results reflect another period of good growth
Following the trading statement on January 25th, CVS has reported interim results to December 31st that reflect strong like-for-like top-line growth and an EBITDA margin of 19.1%, both...
Uniphar
FY2023 results reflect strong organic gross profit growth
Uniphar’s FY2023 results reflect strong organic growth in gross profits of 5.6% year-on-year (yoy). Adjusted EBITDA expanded 18% yoy. Higher interest costs and depreciation charges...
